Ocuphire Pharma Results Presentation Deck

RM 25 Nyxol Comparison to Rev-Eyes Nyxol has a Distinct Commercial Advantage to Rev-Eyes Tolerability Comfort Side effects Commercial Product Presentation No. of drops instilled ● ● Nyxol Mild hyperemia Mild discomfort (38%), erythema (4%), or instillation pain (3%) None reported Stable Preservative-free Sterile Single-unit dose packaging Normo-osmolar solution 1-2 drops/eye ● ● ● ● ● Rev-Eyes Severe hyperemia (80%) Burning/Stinging (50%) 40% (ptosis - droopy eyelids) Requires aseptic technique for reconstitution and mixing at physician office Stable for 21 days after product is reconstituted Contains preservative Hyperosmolar solution 4 drops/eye (2 drops, followed 5 minutes later by 2 additional drops) Source: Rev-Eyes (Dapiprazole HCL) Eyedrops 0.5% Summary Basis of Approval None (0) Normal Appears white with a small number of conjunctival blood vessel easily observed Mild (+1) Prominent, pinkish- red color of both the bulbar and palpebral conjunctiva Nyxol O Moderate (+2) Bright, scarlet red color of the bulbar and palpebral conjunctiva Severe (+3) Beefy red with petechiae, dark red bulbar and palpebral conjunctiva with evidence of subconjunctival hemorrhage Rev-Eyes Ocuphire PHARMA

View entire presentation